Document is current
Any future updates will be listed below
-
Authors
Lu, Yiran
Li, Qingchen
Xu, Lusi
Zheng, Yanqing
Wang, Yanchao
Liu, Ying
Zhang, Rui
Liao, Lin
Dong, Jianjun
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05593744 at ClinicalTrials.govDocuments that mention this clinical trial
Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
https://doi.org/10.1007/s00432-023-05364-z
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No.82100891, No.82170847, No.82170824)
- License Information
-
More Information
Article History
Received: 4 August 2023
Accepted: 28 August 2023
First Online: 15 September 2023
Declarations
:
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: This study was approved by the Ethics Committee of Qilu Hospital of Shandong University and retrospectively registered with ClinicalTrials.gov (NCT 05593744).
: All participants signed informed written consent before being enrolled in the study. This study was performed in line with the principles of the Declaration of Helsinki.
: Not applicable. Because this is not a case study. We collect data anonymously. We present the results by analyzing a large number of quantitative data, and there will be no information leakage of any participants.
